Limba
|
Rozanolixizumab (Anti-FcRn (FCGRT & B2M)) is a high-affinity humanized monoclonal antibody, targeting human neonatal Fc receptor (FcRn) and is used to the research of reducing pathogenic IgG in autoimmune and alloimmune diseases. MW: 150 KD.
| Price | 5.442,00 RON (preturile sunt fara TVA) |
|---|---|
| Description |
Rozanolixizumab (Anti-FcRn (FCGRT & B2M)) is a high-affinity humanized monoclonal antibody, targeting human neonatal Fc receptor (FcRn) and is used to the research of reducing pathogenic IgG in autoimmune and alloimmune diseases. MW: 150 KD. |